miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α

Cancer Biology and Therapy

Volumn 16, Issue 6, 2015, Pages 846-855

  Zhou, Jianda ^a   Xu, Dan ^a   Xie, Huiqing ^a   Tang, Jingtian ^b   Liu, Rui ^a   Li, Jingjing ^a   Wang, Shaohua ^a   Chen, Xiang ^c   Su, Juan ^c   Zhou, Xiao ^a   Xia, Kun ^a   He, Quanyong ^a   Chen, Jia ^a   Xiong, Wei ^a   Cao, Peiguo ^a   Cao, Ke ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cell proliferation; HIF 1 ; Invasion; Melanoma; Metastasis; microRNAs; miR 33a

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 33A; UNCLASSIFIED DRUG; MIRN33 MICRORNA, HUMAN;

A375 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; METASTASIS; MOUSE; NONHUMAN; REPORTER GENE; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE; ANIMAL; DISEASE MODEL; DOWN REGULATION; DRUG SCREENING; GENETICS; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA; MICE; MICRORNAS; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937707378     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1030545     Document Type: Article

References (36)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74; PMID: 21376230; http://dx. doi. org/10. 1016/j. cell. 2011. 02. 013.
2. Segura MF, Greenwald HS, Hanniford D, Osman I, Hernando E. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 2012; 33: 1823-32; PMID: 22693259; http://dx. doi. org/10. 1093/carcin/bgs205.
3. Dong F, Lou D. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis 2012; 18: 537-46; PMID: 22419847.
4. Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek B, Schadendorf D, et al. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 2013; 133: 768-75; PMID: 23151846; http://dx. doi. org/10. 1038/jid. 2012. 357.
5. Dar AA, Majid S, Rittsteuer C, de Semir D, Bezrookove V, Tong S, Nosrati M, Sagebiel R, Miller JR 3rd, Kashani-Sabet M. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 2013; 105: 433-42; PMID: 23365201; http://dx. doi. org/10. 1093/jnci/djt003.
6. Giles KM, Brown RA, Epis MR, Kalinowski FC, Leedman PJ. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun 2013; 430: 706-10; PMID: 23206698; http://dx. doi. org/10. 1016/j. bbrc. 2012. 11. 086.
7. Bhattacharya A, Schmitz U, Wolkenhauer O, Schonherr M, Raatz Y, Kunz M. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene 2013; 32: 3175-83; PMID: 22847610; http://dx. doi. org/10. 1038/onc. 2012. 324.
8. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009; 106: 1814-9; PMID: 19188590; http://dx. doi. org/10. 1073/pnas. 0808263106.
9. Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, Avni D, Leibowitz-Amit R. Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol cancer 2012; 11: 44; PMID: 22747855; http://dx. doi. org/10. 1186/1476-4598-11-44.
10. Chen J, Abi-Daoud M, Wang A, Yang X, Zhang X, Feilotter HE, Tron VA. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2013; 32: 1330-7; PMID: 22665054; http://dx. doi. org/10. 1038/onc. 2012. 141.
11. Xu D, Tan J, Zhou M, Jiang B, Xie H, Nie X, Xia K, Zhou J. Let-7b and microRNA-199a inhibit the proliferation of B16F10 melanoma cells. Oncol Lett 2012; 4: 941-6; PMID: 23162627.
12. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET 3rd, et al. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 2013; 123: 2078-93; PMID: 23563312; http://dx. doi. org/10. 1172/JCI66715.
13. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Näär AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566-9; PMID: 20466882; http://dx. doi. org/10. 1126/science. 1189123.
14. Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011; 108: 9232-7; PMID: 21576456; http://dx. doi. org/10. 1073/pnas. 1102281108.
15. Ramirez CM, Goedeke L, Rotllan N, Yoon JH, Cirera-Salinas D, Mattison JA, Suárez Y, de Cabo R, Gorospe M, Fernández-Hernando C, et al. MicroRNA 33 regulates glucose metabolism. Mol Cell Biol 2013; 33: 2891-902; PMID: 23716591; http://dx. doi. org/10. 1128/MCB. 00016-13.
16. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478: 404-7; PMID: 22012398; http://dx. doi. org/10. 1038/nature10486.
17. Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramirez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion MA, Morales-Ruiz M, Suarez Y, et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle 2012; 11: 922-33; PMID: 22333591; http://dx. doi. org/10. 4161/cc. 11. 5. 19421.
18. Thomas M, Lange-Grunweller K, Weirauch U, Gutsch D, Aigner A, Grunweller A, Hartmann RK. The protooncogene Pim-1 is a target of miR-33a. Oncogene 2012; 31: 918-28; PMID: 21743487; http://dx. doi. org/10. 1038/onc. 2011. 278.
19. Rice SJ, Lai SC, Wood LW, Helsley KR, Runkle EA, Winslow MM, Mu D. MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1 (TTF-1/NKX2-1). J Biol Chem 2013; 288: 16348-60; PMID: 23625920; http://dx. doi. org/10. 1074/jbc. M113. 474643.
20. Kuo PL, Liao SH, Hung JY, Huang MS, Hsu YL. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochimica et biophysica acta 2013; 1830: 3756-66; PMID: 23458685; http://dx. doi. org/10. 1016/j. bbagen. 2013. 02. 022.
21. Friedman EB, Shang S, de Miera EV, Fog JU, Teilum MW, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando E, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 2012; 10: 155; PMID: 22857597; http://dx. doi. org/10. 1186/1479-5876-10-155.
22. Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X. Loss of microRNA-205 expression is associated with melanoma progression. Lab Invest 2012; 92: 1084-96; PMID: 22525428; http://dx. doi. org/10. 1038/labinvest. 2012. 62.
23. Liu S, Kumar SM, Lu H, Liu A, Yang R, Pushparajan A, Guo W, Xu X. MicroRNA-9 up-regulates Ecadherin through inhibition of NF-kappaB1-Snail1 pathway in melanoma. J Pathol 2012; 226: 61-72; PMID: 22131135; http://dx. doi. org/10. 1002/path. 2964.
24. Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 2013; 32: 2984-91; PMID: 22797068; http://dx. doi. org/10. 1038/onc. 2012. 307.
25. Nys K, Maes H, Dudek AM, Agostinis P. Uncovering the role of hypoxia inducible factor-1alpha in skin carcinogenesis. Biochimica et biophysica acta 2011; 1816: 1-12; PMID: 21338656.
26. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 2005; 8: 443-54; PMID: 16338658; http://dx. doi. org/10. 1016/j. ccr. 2005. 11. 005.
27. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010; 46: 1159-69; PMID: 20185296; http://dx. doi. org/10. 1016/j. ejca. 2010. 01. 031.
28. Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 2007; 249: 188-97; PMID: 16997457; http://dx. doi. org/10. 1016/j. canlet. 2006. 08. 016.
29. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003; 13: 493-501; PMID: 14512791; http://dx. doi. org/10. 1097/00008390-200310000-00008.
30. Victor N, Ivy A, Jiang BH, Agani FH. Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. Clin Exp Metastasis 2006; 23: 87-96; PMID: 16826425; http://dx. doi. org/10. 1007/s10585-006-9024-z.
31. Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 2012; 31: 2461-70; PMID: 21996743; http://dx. doi. org/10. 1038/onc. 2011. 425.
32. -2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002; 16: 1453-5; PMID: 12205045.
33. Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Ballot C, Balayssac S, Valable S, et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 2012; 72: 5035-47; PMID: 22865452; http://dx. doi. org/10. 1158/0008-5472. CAN-12-0979.
34. Paradziej-Lukowicz J, Skwarska A, Peszynska-Sularz G, Brillowska-Dabrowska A, Konopa J. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF) and angiogenesis. Cancer Biol Ther 2011 12: 586-97; PMID: 21775820; http://dx. doi. org/10. 4161/cbt. 12. 7. 15980.
35. Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L, Levin B, Meruelo D, Osman I, Zavadil J, et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011; 30: 1481-8; PMID: 21102518; http://dx. doi. org/10. 1038/onc. 2010. 523.
36. Chen X, Lin J, Kanekura T, Su J, Lin W, Xie H, Wu Y, Li J, Chen M, Chang J. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 2006; 66: 11323-30; PMID: 17145878; http://dx. doi. org/10. 1158/0008-5472. CAN-06-1536.